Cargando…
Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
Obesity is an emerging disease worldwide. Changes in living habits, especially with increased consumption of high-calorie foods and decreased levels of physical activity, lead to an energy imbalance that brings weight gain. Overweight and obesity are major risk factors for several chronic diseases (...
Autores principales: | Caixàs, Assumpta, Albert, Lara, Capel, Ismael, Rigla, Mercedes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174046/ https://www.ncbi.nlm.nih.gov/pubmed/25258511 http://dx.doi.org/10.2147/DDDT.S55587 |
Ejemplares similares
-
Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Buehler, Anna M
Publicado: (2015) -
Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion
por: Halseth, A., et al.
Publicado: (2018) -
Method‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity
por: Halseth, Amy, et al.
Publicado: (2016) -
Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
por: Hollander, Priscilla, et al.
Publicado: (2013) -
Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012)